LAUSR

To assess the impact of intrawound vancomycin on surgical site wound infections in non‐spinal neurosurgical operations, we conducted a meta‐analysis. A thorough review of the literature up to September 2022 showed that 4286 participants had a non‐spinal neurosurgical operation at the start of the investigations; 1975 of them used intrawound vancomycin, while 2311 were control. Using dichotomous or contentious methods and a random or fixed‐effect model, odds ratios (OR) and mean difference (MD) with 95% confidence intervals (CIs) were estimated to evaluate the impact of intrawound vancomycin on surgical site wound infections in non‐spinal neurosurgical operation. The intrawound vancomycin had significantly lower surgical site wound infections (OR, 0.28; 95% CI, 0.19‐0.40; P < .001) with low heterogeneity (I2 = 32%) compared with the control in non‐spinal neurosurgical operation. The intrawound vancomycin had significantly lower surgical site wound infections compared with control in non‐spinal neurosurgical operation. The low sample size of 2 out of 13 researches in the meta‐analysis calls for care when analysing the results.